Clinical Trials
20 trialsNCT05906537 2026-05-12
SKB410 for Injection in Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1 Active not recruiting
NCT05083481 2026-05-05
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
Astellas Pharma Inc
Phase 1/2 Active not recruiting
NCT05109975 2026-04-28
A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors
Debiopharm International SA
Phase 1 Active not recruiting
NCT05605496 2026-04-24
IMMUNONET
Centre Leon Berard
Phase 2 Active not recruiting
NCT05951608 2026-04-23
A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors
Akeso
Phase 1/2 Active not recruiting
NCT05781048 2026-03-10
A Phase I Clinical Study of the Safety， Tolerability，Pharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Active not recruiting
NCT06715124 2026-03-02
QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations
Quanta Therapeutics
Phase 1 Active not recruiting
NCT05914376 2026-02-27
Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors
Hangzhou Converd Co., Ltd.
Phase 1 Active not recruiting
NCT06341114 2025-12-08
A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors
Bio-Thera Solutions
Phase 1/2 Active not recruiting
NCT04185883 2025-10-22
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Amgen
Phase 1 Active not recruiting
NCT04058756 2025-10-07
Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments
Novartis
Phase 1 Active not recruiting
NCT03191682 2025-09-25
A First-in-Human Study of PRL3-ZUMAB
National University Hospital, Singapore
Phase 1 Active not recruiting
NCT07122063 2025-08-14
Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 1/2 Active not recruiting
NCT05718219 2025-08-13
Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0348 in Advanced Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1 Active not recruiting
NCT05740202 2025-08-05
A Trial of SHR-7367 in Subjects With Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1 Active not recruiting
NCT06610227 2025-07-16
A Study of the RNA Tumor Vaccine Targeting MICA/B in Patients With Advanced Solid Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase EARLY_PHASE1 Active not recruiting
NCT06076291 2025-06-27
CSG-1827-101
Hangzhou Sumgen Biotech Co., Ltd.
Phase 1 Active not recruiting
NCT06235983 2025-04-18
A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Active not recruiting
NCT06723964 2024-12-09
A Study of AP505 Injection in Patients With Advanced Malignant Solid Tumors
AP Biosciences Inc.
Phase 1 Active not recruiting
NCT05731752 2024-07-22
Study on the Tolerability and Pharmacokinetics of HX009 in Patients With Advanced Solid Tumors
Hangzhou Hanx Biopharmaceuticals, Ltd.
Phase 1 Active not recruiting